Newsroom

ANTWERPEN, België--(BUSINESS WIRE)--GEREGULEERDE INFORMATIE In overeenstemming met artikel 14 van de Belgische Transparantiewet van 2 mei 2007 maakt Azelis Group NV (Brussels:AZE) bekend dat het twee transparantiekennisgevingen heeft ontvangen van UBS Group AG op 13 oktober 2026. 1. Samenvatting van de kennisgevingen UBS Group AG heeft in een eerste kennisgeving gedateerd op 13 oktober 2026 gemeld dat op 8 oktober 2026, na een verwerving van aandelen met stemrecht en van gelijkgestelde financië...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Paris:POXEL) (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies à physiopathologie métabolique, dont la stéatohépatite associée à un dysfonctionnement métabolique (MASH) et les maladies métaboliques rares, publie aujourd'hui son chiffre d'affaires pour le troisième trimestre clos le 30 septembre 2026 et les neuf premiers mois de l’exercice. Bilan de l’act...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announces its revenue for the third quarter ended September 30, 2026, and for the first nine months of the fiscal year. Commercial Activity Update T...

ANTWERP, Belgium--(BUSINESS WIRE)--REGULATED INFORMATION In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV (Brussels:AZE) announces that on 13 October 2026, it has received two transparency notifications from UBS Group AG. 1. Summary of the notifications UBS Group AG reported in its first notification dated 13 October 2026, that on 8 October 2026, following an acquisition of shares with voting rights and equivalent financial instruments, UBS Group AG (...

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”) today provides an update on its Product Services’ (“BW Product Services”) Q3 2026 segment performance. Q3 2026 highlights: Gross trading result: US$164 million This includes: Realised trading result of US$146 million Positive unrealised mark-to-market movement of US$18 million Net profit after general and administrative expenses and income taxes: US$118 million Average V...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Mon courtier énergie groupe (code ISIN : FR001400H3A0 - Mnémonique : ALMCE), société de courtage en énergie pour les entreprises, annonce aujourd’hui ses résultats du premier semestre 2026. Webinaire de présentation Ce Lundi 19 octobre 2026 à 12h (CEST) INSCRIVEZ-VOUS ICI Hugo LARRICQ, Président Directeur Général de Mon courtier énergie groupe, déclare : « Mon courtier énergie groupe publie de très bons résultats au titre du premier semestre 2...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Mon courtier énergie group (ISIN code: FR001400H3A0 - Ticker: ALMCE), an energy brokerage company for businesses, today announces its results for the first half of 2026. Results presentation webinar This Monday, 19 October 2026 at 12:00 (CEST) REGISTER HERE Hugo LARRICQ, Chairman and Chief Executive Officer of Mon courtier énergie group, said: “Mon courtier énergie group is reporting very strong results for the first half of 2026, marked by a...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer...

OXFORD, England--(BUSINESS WIRE)--Infleqtion (NYSE: INFQ), a global leader in quantum computing and quantum sensing powered by neutral atom technology, will host the first Quantum Application Forum, an exclusive one-day event convening senior business and technology leaders on 3 November 2026 at IET Savoy Place in London. Executives responsible for technology, innovation and investment decisions will explore how quantum technology can address critical challenges, unlock commercial value and dri...

BASEL, Switzerland & MUNICH & BELOIT, Wis.--(BUSINESS WIRE)--NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, LLC (NorthStar), a global radiopharmaceutical supply-chain partner, today announced a long-term strategic partnership through which NorthStar will produce Copper-67 (Cu-67) and provide comprehensive radiopharmaceutical manufacturing services to support NUCLIDIUM's therapeutic programs from clinical development through commercialization. Cop...